GSK Kills Camlipixant: The $2B Bellus Bet Unravels

GSK just killed the chronic cough drug it paid two billion dollars for — and it's the third drug in its class to die the same way.

Meanwhile Jasper pulled off a last-minute lifeline merger, Novartis locked down full approval in IgA nephropathy, and Lilly wrote a two-point-eight-billion-dollar check into psychedelics. Busy Friday. Let's get into it.

Welcome to The Pharma Closeout for Friday, July 17th. I'm Alex Mercer.

And I'm Maya Patel.

Start with GSK. About twelve hours ago they discontinued camlipixant — the Phase 3 chronic cough program that was the entire reason they bought Bellus Health for roughly two billion dollars. Mixed late-stage data, and they walked.

So walk through what they thought they were buying. That's where this actually hurts.

Bellus was a bet on the P2X3 pathway in refractory chronic cough — a real unmet need, patients who cough for years with nothing that works. Camlipixant was the cleaner, more selective option. Except now it's the third molecule from that class to fail.

OK, but here's my issue with calling this a class verdict. Chronic cough is one of the noisiest indications in all of respiratory. The primary endpoint is twenty-four-hour cough frequency — sounds objective, but the placebo response is enormous. Patients get counted, they get attention, the cough count drops on placebo alone. Pulling a real drug effect out of that noise is brutal.

That's fair — the endpoint is unforgiving. But three molecules in a row is a pattern, and the street is going to price it as mechanism risk whether or not that's the honest read. And I'd add that the selectivity angle was supposed to be the differentiator here. Camlipixant was pitched as the cleaner P2X3 — fewer taste-related side effects, better tolerability, a molecule designed to fix the exact problems the first-generation compounds ran into. So when the cleaner version still can't clear the bar, the market doesn't hear "we need an even cleaner molecule." It hears "the target itself is the problem."

Then the honest read is the more interesting one. This may be less "P2X3 doesn't work" and more "refractory chronic cough is an indication where the endpoint is so noisy that even a working drug can't reliably clear the bar." That completely changes what GSK's write-down means. It's not a bad molecule they overpaid for. It might be a bad indication to develop against at all. And those two diagnoses lead to completely different next moves. If it's the molecule, you keep hunting the pathway. If it's the indication, you stop — full stop — because no amount of chemistry saves you from an endpoint that won't hold still.

And that's the expensive lesson. GSK's staring at an impairment on Bellus, and the competitive read is clean. If you run respiratory business development and you had a P2X3 or a chronic cough asset in your bolt-on models, the question just flipped — from "is our molecule better than GSK's" to "can anything separate from placebo here." Two billion dollars to answer that.

And think about what that does to diligence going forward. Every board that looks at a cough asset now has three dead programs sitting on the table as the base rate. You can't walk into an investment committee and argue your Phase 2 signal is real when the field's track record in Phase 3 is zero for three. The burden of proof effectively moves to needing a confirmatory replication before anyone commits real money — which is exactly the kind of capital and time most of these smaller developers don't have.

Which is how a real unmet need just gets orphaned by arithmetic. The biology could still be right, and it wouldn't matter.

And the open thread is whether anyone stays in to try. Because once three programs die, the money leaves. A genuinely underserved cough population loses its pipeline — not because the biology was disproven, but because the trial design beat everyone who walked in.

From a two-billion-dollar retreat to a lifeline. Jasper Therapeutics closed an all-stock merger with Kira Pharmaceuticals and bolted a one-hundred-and-thirty-two-million-dollar private placement onto it. Stock jumped more than twenty percent. This funds the combined company into the second half of 2028 — after most of Jasper's market value had already evaporated.

The tell is what they didn't keep. Kira out-licensed its two lead complement assets — the anti-C5a antibody and the C5a receptor antagonist — to Mirador for twelve million dollars upfront. You don't hand off your C5a programs for twelve million if you believe they're the franchise. What Jasper kept is the dual-complement inhibitor in PNH and nephrology, plus the anti-KIT antibody. That's the real bet.

And Mirador's aiming that licensed asset straight at Tavneos, which has had a rough launch. One company's cast-off becomes another's wedge. That's the part I find telling on valuation — twelve million upfront says the seller had no leverage, but Mirador clearly sees a lane. A struggling incumbent launch is an invitation, and picking up the challenger asset cheap is a low-risk way to test whether you can exploit it.

It's a reverse-merger rescue wearing a pipeline-consolidation suit. The runway buys them multiple readouts. The question is whether the assets they held onto are the better science — or just the ones nobody would pay more than twelve million for.

And that's the uncomfortable ambiguity in every one of these rescues. Runway into the second half of 2028 sounds like breathing room, but it only matters if what you kept can generate a value-inflecting readout inside that window. Dual-complement in PNH is a crowded, well-defended space. So the clock isn't just about survival — it's about whether the surviving asset can prove itself before the money runs out again.

Right, and a merged company that consolidated to survive still has to answer the original question that got it into trouble — is the science good enough to fund on its own merits next time?

Couple more, quick. We flagged Lilly's next move yesterday — here it is. Two-point-eight billion upfront for AtaiBeckley, a psychedelics play in depression. Lilly using its cash to reach into severe mental illness, miles from the obesity story everyone watches. Pfizer, meanwhile, got cut to Hold — analysts pointing at delayed pipeline catalysts and management churn eating into any near-term re-rating. And in oncology, Merck put out data on its ADC sac-TMT in a China lung cancer study that Wall Street called direct proof-of-concept it could eventually stand in for chemo in front-line disease.

The Pfizer downgrade is the one that should sting. When analysts move from "when do the catalysts hit" to "we'll wait and see," that's the market saying the pipeline isn't generating its own momentum. Contrast that with the same afternoon — Lilly buying into a new therapeutic area from a position of strength, and Merck showing a cornerstone asset might reset a front-line standard. Two companies playing offense. One being told to prove it.

And the Lilly move deserves a second look on strategy, because reaching into psychedelics for depression is a diversification play from someone who doesn't need to diversify. That's the interesting part — they're spending obesity-era cash to buy an option in a completely different disease area, which tells you they're thinking about what the portfolio looks like well after the current growth story matures. That's a company managing the next decade, not the next quarter.

And Merck's read-through matters beyond Merck. If an ADC can credibly stand in for chemotherapy in front-line lung cancer, that's not just one asset — it's a signal about where the whole standard of care is heading. Everyone with a front-line chemo backbone in their regimen has to re-underwrite the durability of that position.

On the regulatory front, the headline is Novartis. Fabhalta converted from accelerated to full approval in IgA nephropathy — and this is confirmatory data actually doing its job. Per the company, it slowed annualized eGFR decline to three-point-zero versus five-point-seven on placebo over two years. Roughly forty-eight percent slower kidney function loss.

And we were standing in this exact space last week with Vera's IgAN approval. The market's filling up fast.

Fast — Fabhalta's now joined a growing roster of approved options in this disease area, and Novartis owns two of them, Vanrafia already on the board. But the label-first read is what matters. The FDA didn't gate eligibility by proteinuria level. A broad label, in a progressive disease where up to half of patients eventually head toward dialysis — that's the commercial engine. Not the approval headline.

And owning two of the approved options changes the competitive dynamic entirely. Novartis isn't just competing in IgAN — they can build a whole franchise strategy around it, sequence the two products, own the prescriber relationship end to end. When one company holds two shots on goal in a filling market, the incremental entrant has to fight not just for approval but for share against a player who's already anchored in the treatment algorithm.

And here's the detail worth catching: Novartis got the confirmatory eGFR evidence read out and accepted early, instead of waiting the full expected window — the same accelerated-timeline logic Vera negotiated. The agency will move faster on confirmatory endpoints when the effect size is genuinely there.

Which is a quiet gift to anyone developing in kidney disease — it says a strong, clean effect buys you time back on the regulatory calendar.

But it cuts both ways. That same speed quietly raises the bar for everyone still owing confirmatory data behind them. If the agency will accelerate when the effect is real, then a slow or hedged confirmatory readout starts to look like a tell — the absence of speed becomes its own signal. Also worth noting on the regulatory side — Novo Nordisk and Alvotech both got written up after FDA site inspections. Manufacturing citations don't make headlines. But for a company like Novo, running flat-out on supply, an inspection finding is exactly the kind of thing that throttles the launch you're trying to scale.

And that's the underrated risk in the whole GLP-1 gold rush — the constraint was never demand, it's the ability to make the product reliably at volume. A citation on the manufacturing side is a direct tax on the one thing that's actually scarce.

Looking ahead — GSK is launching a large study on whether the shingles vaccine can help prevent Alzheimer's. Early, long readout. But the epidemiological signal has been building for years, and if it holds, it turns a mature vaccine into something much bigger.

And it's a fascinating hedge coming the same week they wrote off camlipixant. One arm of the company takes an expensive loss on a bought-in asset while another places a long-dated bet that could reframe a product they already own. That's the portfolio logic of a company that has to keep multiple time horizons alive at once.

And if that signal holds, the economics are asymmetric — you're not paying to develop a new molecule, you're expanding the addressable population of an asset that's already made and already sold. That's the cheapest kind of upside there is.

And two threads still hanging. Novartis' pelacarsen — the big Lp(a) cardiovascular outcomes readout was expected in the first half of this year. We're past that, and it hasn't landed. We're not going to guess the outcome. But when it comes, it's a franchise-definer, so it stays on the board.

And the IPO window keeps creaking open. Scribe Therapeutics filed to go public earlier this month under the ticker SCTX — no pricing yet — and the queue behind it keeps growing. That's the real sentiment tell: capital is willing to take early-stage biotech public again.

Here's the through-line for the whole week. Capital discipline running straight into capital appetite. GSK wrote off a two-billion-dollar mistake in the same five days Lilly wrote a two-point-eight-billion-dollar check into brand-new territory. The market's rewarding conviction and punishing drift. That's the frame you carry into Monday.

And that is your Pharma Closeout for Friday, July 17th — GSK abandoning camlipixant, Jasper's lifeline merger, Fabhalta's full approval in IgAN, Lilly's psychedelics swing. One week, the entire spectrum from write-off to bold bet. If someone on your team needs to be across this week in pharma, send them the feed — and if the briefing saves you time, follow us on Spotify and drop a rating.

Go enjoy your weekend — there's plenty to chew on. We'll be back Sunday with the Weekend Closeout. See you then!